Showing results (1-10 of 256) with videos related to
Sort By:
Pageof 26
Cytokine & Growth Factor Reviews|December 18, 2002
Non-apoptotic Fas signalingHarald Wajant, Klaus Pfizenmaier, Peter ScheurichPlos One|November 24, 2011
A TNF receptor 2 selective agonist rescues human neurons from oxidative stress-induced cell deathRoman Fischer, Olaf Maier, Martin Siegemund, et al.The FEBS Journal|January 15, 2011
TNFR1-induced activation of the classical NF-κB pathwayHarald Wajant, Peter ScheurichCytokine & Growth Factor Reviews|March 1, 2005
Tumor therapeutics by design: targeting and activation of death receptorsHarald Wajant, Jeannette Gerspach, Klaus PfizenmaierRecent Patents on Anti-Cancer Drug Discovery|July 19, 2011
Therapeutic targeting of CD95 and the TRAIL death receptorsJeannette Gerspach, Klaus Pfizenmaier, Harald WajantCancer Letters|January 18, 2011
Engineering death receptor ligands for cancer therapyHarald Wajant, Jeannette Gerspach, Klaus PfizenmaierBiofactors (Oxford, England)|June 2, 2009
Improving TNF as a cancer therapeutic: tailor-made TNF fusion proteins with conserved antitumor activity and reduced systemic side effectsJeannette Gerspach, Klaus Pfizenmaier, Harald WajantResults and Problems in Cell Differentiation|January 15, 2009
Death ligands designed to kill: development and application of targeted cancer therapeutics based on proapoptotic TNF family ligandsJeannette Gerspach, Harald Wajant, Klaus PfizenmaierBiochemical and Biophysical Research Communications|May 8, 2010
Superior serum half life of albumin tagged TNF ligandsNicole Müller, Britta Schneider, Klaus Pfizenmaier, et al.Expert Opinion on Drug Discovery|March 16, 2013
Antagonists of TNF action: clinical experience and new developmentsRoland E Kontermann, Peter Scheurich, Klaus PfizenmaierPageof 26